In contrast with Tan [6] and Lim [10], who found that genes upregulated in MED12-mutant FAs were associated with ER+ breast cancers, estrogen stimulus in ER+ breast cancer cells and activated estrogen signaling, we did not find any link between MED12 and ESR1 signaling pathways. This evidence concerns the gene MED12 and breast carcinoma.